Show simple item record

dc.contributor.authorBarry, Michael
dc.date.accessioned2014-08-20T15:20:26Z
dc.date.available2014-08-20T15:20:26Z
dc.date.issued2013-09
dc.identifier.citationBarry M.Medicines management programme: preferred medicines angiotensin-converting enzyme inhibitors. Dublin: Health Service Excutive; 2013. 12p.en_GB
dc.identifier.urihttp://hdl.handle.net/10147/325028
dc.descriptionThere are ten licensed angiotensin‐converting enzyme (ACE) inhibitors available in Ireland.1 Annual expenditure on ACE inhibitors under the General Medical Services (GMS) scheme exceeds an estimated €15 million.2 The selection of a preferred ACE inhibitor under the Medicines Management Programme (MMP) is designed to support prescribers in choosing a medicine of proven safety and efficacy in the management of patients with cardiovascular conditions, particularly hypertension and heart failure. In selecting a preferred ACE inhibitor the MMP aims to enhance the quality of prescribing and provide value for money. The guidance may not be applicable to all patient populations, e.g. children and patients with congenital cardiac conditions, in which circumstances specialist advice should be sought. The use of ACE inhibitors is not recommended during the first trimester of pregnancy. ACE inhibitors are contraindicated during the second and third trimesters of pregnancyen_GB
dc.language.isoenen
dc.publisherHealth Service Excutive (HSE)en_GB
dc.relation.urlhttp://www.hse.ie/yourmedicinesen_GB
dc.subjectMEDICINEen_GB
dc.subjectDRUGen_GB
dc.titleMedicines management programme: preferred medicines angiotensin-converting enzyme inhibitorsen_GB
dc.typeReporten
dc.contributor.departmentHealth Service Executiveen_GB
refterms.dateFOA2018-08-24T17:20:13Z


Files in this item

Thumbnail
Name:
medicinesmanageprog.pdf
Size:
315.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record